Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2012 Aug;19(4):681-92.
doi: 10.1007/s12350-012-9547-4. Epub 2012 Apr 7.

A randomized, double-blind, placebo-controlled study assessing the safety and tolerability of regadenoson in subjects with asthma or chronic obstructive pulmonary disease

Bruce M Prenner  1 , Stan Bukofzer, Sarah Behm, Kathleen Feaheny, Bruce E McNutt
Affiliations
Clinical Trial

A randomized, double-blind, placebo-controlled study assessing the safety and tolerability of regadenoson in subjects with asthma or chronic obstructive pulmonary disease

Bruce M Prenner et al. J Nucl Cardiol. 2012 Aug.

Abstract

Background: Adenosine receptor stress agents for myocardial perfusion imaging (MPI) may cause A(2B) and/or A(3) receptor-mediated bronchoconstriction, of particular concern to physicians testing patients with asthma or chronic obstructive pulmonary disease (COPD).

Methods: A Phase 4, randomized, double-blind study (NCT00862641) assessed the safety of the selective A(2A) receptor agonist, regadenoson, compared with placebo in subjects with asthma or COPD who represented likely candidates for MPI.

Results: Overall, 356 and 176 subjects with asthma and 316 and 151 subjects with COPD received regadenoson and placebo, respectively. The percentage of subjects experiencing a >15% decrease in FEV(1) from baseline to any assessment up to 24 hours post-baseline was not statistically significantly different between the regadenoson and the placebo groups in the asthma or COPD stratum. Dyspnea, the most frequent respiratory adverse event, occurred with higher incidence (P < .0001) in the regadenoson group than the placebo group in the asthma (10.7% vs 1.1%) and COPD (18.0% vs 2.6%) strata. No subjects experienced severe bronchoconstriction, although the occurrence of such reactions with adenosine receptor agonists cannot be ruled out, such that caution is advised.

Conclusions: This information may be helpful to physicians selecting a pharmacologic stress agent for MPI in patients with asthma or COPD.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Subject disposition flow diagrams for the asthma (A) and COPD (B) disease strata
See this image and copyright information in PMC

Comment in

References

    1. Henzlova MJ, Cerqueira MD, Taillefer R, Mahmarian JJ, Yao SS, Quality Assurance Committee of the American Society of Nuclear Cardiology. Stress protocols and tracers. J Nucl Cardiol 2009. doi:10.1007/s12350-009-9062-4. - PubMed
    1. Belardinelli L, Shryock JC, Snowdy S, et al. The A2A adenosine receptor mediates coronary vasodilation. J Pharmacol Exp Ther. 1998;284:1066–1073. - PubMed
    1. Cerqueira MD. Advances in pharmacologic agents in imaging: New A2A receptor agonists. Curr Cardiol Rep. 2006;8:119–122. doi: 10.1007/s11886-006-0022-1. - DOI - PubMed
    1. Gao Z, Li Z, Baker SP, et al. Novel short-acting A2A adenosine receptor agonists for coronary vasodilation: Inverse relationship between affinity and duration of action of A2A agonists. J Pharmacol Exp Ther. 2001;298:209–218. - PubMed
    1. Leaker BR, O’Connor B, Hansel TT, et al. Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: A randomized, double-blind, placebo-controlled trial. J Nucl Cardiol. 2008;15:329–336. doi: 10.1016/j.nuclcard.2008.02.009. - DOI - PubMed

Publication types